Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
Non-profit, non-governmental organisation providing independent information on drugs to health professionals and promoting Rational Prescribing.
Funded by the Belgian Federal Agency for Drugs and Health Products (AFMPS/FAGG)
History: founded in 1974 by the Belgian Professors of Pharmacology and headed during 30 years by Prof. M. Bogaert
Major Strenghts: COMBINATION OF Information Education Warnings (pharmacovigilance) Service (prescription modalities, availability…) PERCEIVED AS RELIABLE & INDEPENDENT BY HEALTH WORKERS
Mission Statement / Structure / History
The Belgian Centre for Pharmacotherapeutical Information (BCFI/CBIP):
Independent drug information for Belgian health professionnals
Chief Editors: Prof. T. Christiaens, Dr. G. De Loof , Prof. J.M. Maloteaux.
.
First edition of Repertorium (1979) and edition 2007
CBIP/BCFI promotes Rational Prescribing
Numerous definitions for rational prescribing have been suggested, but essentially it is a balancing act
that centres around four major components:
-Maximising effectiveness
-Minimising risk
-Minimising cost
-Respecting patient choice.
Barber N. What constitutes good prescribing? BMJ 1995;310:923-5
Written Information
Répertoire Commenté des Médicaments/
Gecommentarieerd Geneesmiddelenrepertorium •General Informations on prescribing, intoxications, interactions and side-effects, specific problem situations (children,
pregnancy) …
•All drugs on the Belgian market classified with practical data (dosages, forms) and some comments
Folia Pharmacotherapeutica • Recent Informations
• Thematic Articles
• « Goed om te Weten »/ « Bon à savoir »: recent information
•News from the pharmacovigilance (in collaboration with BCGH/ CBPH)
Transparantiefiches/ Fiches de transparence • Overview of all available evidence on drug treatment of a specific clinical problem
•Comparison of prices and side effects
WEBSITE
www.cbip.be (French) OR www.bcfi.be (Dutch)
Independent Pharmacotherapeutic Information
(Journal-Club function)
• « Pivotal trials »
• Critical appraisals, reviews on clinical topics
•Trial methodology
Information on new drugs •Information on new drug classes and mechanisms
•Information about « me-too ’s» and pseudo-innovations
•Information about efficacy (with emphasis on absolute risk reductions,
NNT’s) but also on side effects
•Positioning amongst existing therapeutic possibilities (comparative efficacy
and security and prices)
Target group
All documents are sent free of charge to
43.000 physicians,
16.000 pharmacists, 8.000 dentists,
16.000 students.
>2000 Repertories sent to European and
African partners and health workers
The website is open to all
B.C.F.I./C.B.I.P. Eurostation,bloc II, 8th floor, 40 Place Victor Horta, PB 40, 1160 Brussels, Belgium
mail: [email protected] OR [email protected]
Publications of BCFI/CBIP
•Peer-Reviewed top-journals (N. Engl. J. Med.; Lancet; BMJ; …) and Journal-Clubs (Minerva, ACPJC,...)
•Registration authority reports (EMEA)
•Prescrire, Drug &Therapeutics Bulletin…(International Society of Drug Bulletins)
•Pharmacovigilance Agencies: Belgian Centre of Pharmacovigilance, EMEA, FDA, Lareb
•Health Technology Assessment Organisations (KCE, NICE, HAS...), Cochrane Collaboration
•Belgian expert network
Information sources:
Veterinary Repertory
All the “traditional” publications
+ FOLIA EXPRESS: e-mail alerts for major news
Price comparisons within
drug classes
Planned Initiatives:
•Adapt information in regard to DCI prescribing and electronic prescribing
•Provide information aimed specifically at the public (in collaboration with FAGG/AFMPS)
•Set up a system for e-learning
“Yellow Card”:ADR
reporting form (in collaboration with
pharmacovigilance
BCGH/ CBPH)